About 1 in 7 users (14.6%) of injectable GLP-1 receptor agonists (RAs) have taken or are taking them at lower doses than those approved by the FDA, and many decided to do so without clinician input, a new survey found.

The most common reasons for GLP-1 RA microdosing are to manage tolerability, save money, and transition from weight loss to weight maintenance, according to the survey by Evidation, a California-based company that gathers healthcare information directly from members via its app.

The situation was far different among respondents who were actively microdosing — only 39.8% of them said they got their medication from their current healthcare clinician. Almost 24% reported getting their GLP-1 RA from a telehealth service. Less common sources included med spas, weight-loss clinics and directly from the manufacturer.

Telemedicine services typically offer lower-cost compounded versions of GLP-1 RAs, making them an attractive option for patients, noted an article in Medscape Medical News.

When asked about their most trusted source of information on microdosing, a larger percentage of GLP-1 RA users answered social media (26.8%) and online research (24.4%) than answered their healthcare clinician (20.3%).